Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02308202 · ClinicalTrials.gov registry record · Phase 1
Doxazosin FOR Ptsd
A Phase 1 study of PTSD, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02308202: Completed Phase 1 study of PTSD, sponsored by Baylor College of Medicine.
NCT02308202 is a Phase 1 study of PTSD that has completed, run by Baylor College of Medicine. The registered enrollment target is 30 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02308202, a Phase 1 study of PTSD, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this study is to determine the effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy on Post Traumatic Stress Disorder. The effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy will be assessed in double-blind, placebo-controlled study. The study will enroll 30 participants. The investigators will use a within groups design in which all participants receive both placebo and doxazosin (N=16) with the order counterbalanced across participants. A second group of patients (N=16) will receive both 16mg perindopril and placebo instead of doxazosin/placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG doxazosin
- DRUG Perindopril
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-06-30 |
| Phase | Phase 1 |
What the finished NCT02308202 record still lists
NCT02308202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (90% lower).
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02308202 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02308202 about?
NCT02308202 is a clinical study titled "Doxazosin FOR Ptsd". The aims of this study is to determine the effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy on Post Traumatic Stress Disorder. The effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy will be assessed in...
What is the current status of trial NCT02308202?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-01. Estimated completion is 2014-06-30.
What conditions does trial NCT02308202 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT02308202?
The interventions under investigation include: Placebo (DRUG), doxazosin (DRUG), Perindopril (DRUG).
Who is sponsoring clinical trial NCT02308202?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02308202 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02308202's enrollment target sits among peer trials
30 122nd of 154 higher than 25 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Psilocybin Study in Transdiagnostic Population
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD
RECRUITING · Phase 1
-
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
ACTIVE NOT RECRUITING · Phase 1
-
Methylphenidate for Ptsd and Stroke Veterans
COMPLETED · Phase 1
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia